Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load

(2019) Anita Schuch et al.   GUT

Immunological cure of HBV infection

(2019) Julia Lang et al.   Hepatology International

Liver sampling: a vital window into HBV pathogenesis on the path to functional cure

(2018) Upkar S Gill et al.   GUT

Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation

(2018) Laura Rivino et al.   JOURNAL OF CLINICAL INVESTIGATION

Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination

(2018) Claudia Dembek et al.   Current Opinion in Virology

A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

(2018) Roland Kratzer et al.   Human Vaccines & Immunotherapeutics

Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients

(2018) Barbara Testoni et al.   JOURNAL OF HEPATOLOGY

Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5′-UTR ofTRIM22

(2017) Keo-Heun Lim et al.   GUT

Chronic hepatitis B: Immunological profile and current therapeutic vaccines in clinical trials

(2017) Yadira Lobaina et al.   VACCINE

Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts

(2017) et al.   Viruses-Basel

New therapeutic agents for chronic hepatitis B

(2016) Mayur Brahmania et al.   LANCET INFECTIOUS DISEASES

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

(2016) Elisabeth Quoix et al.   LANCET ONCOLOGY

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D

(2015) B. Maasoumy et al.   CLINICAL MICROBIOLOGY AND INFECTION

Effect of vaccine administration modality on immunogenicity and efficacy

(2015) Lu Zhang et al.   Expert Review of Vaccines

Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes

(2015) Ophelie Godon et al.   VACCINE

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

(2014) Perrine Martin et al.   GUT

Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation

(2014) Bertram Bengsch et al.   JOURNAL OF HEPATOLOGY

Epitope Specificity Delimits the Functional Capabilities of Vaccine-Induced CD8 T Cell Populations

(2014) Brenna J. Hill et al.   JOURNAL OF IMMUNOLOGY

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)

(2014) Mary E. Enama et al.   PLoS One

Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: A dose and route conundrum

(2014) Shakti Singh et al.   VACCINE

Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization

(2013) K. M. Quinn et al.   JOURNAL OF IMMUNOLOGY

A Human Type 5 Adenovirus-Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity

(2013) F. Smaill et al.   Science Translational Medicine

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

(2012) Carolina Boni et al.   GASTROENTEROLOGY

Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection

(2011) Antonio Bertoletti et al.   GUT

Transcutaneous and intradermal vaccination

(2011) Behazine Combadiere et al.   Human vaccines & immunotherapeutics

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

(2011) Cindy Tamminga et al.   PLoS One

The molecular basis of the failed immune response in chronic HBV: Therapeutic implications

(2010) Mala K. Maini et al.   JOURNAL OF HEPATOLOGY

A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

(2010) Hannah Kibuuka et al.   JOURNAL OF INFECTIOUS DISEASES

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

(2010) J.E. Ledgerwood et al.   VACCINE

Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B

(2009) Paola Fisicaro et al.   GASTROENTEROLOGY

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

(2008) Frances H. Priddy et al.   CLINICAL INFECTIOUS DISEASES

Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection

(2008) A. Ross Lopes et al.   JOURNAL OF CLINICAL INVESTIGATION

Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection

(2008) Abhishek Das et al.   JOURNAL OF EXPERIMENTAL MEDICINE